Cargando…

Evaluating Upadacitinib in the Treatment of Moderate-to-Severe Active Ulcerative Colitis: Design, Development, and Potential Position in Therapy

Upadacitinib is a selective small molecule that inhibits Janus kinase (JAK) type 1. This molecule is administrated orally and is currently approved for the treatment of rheumatoid arthritis, atopic dermatitis, and psoriatic arthritis. Upadacitinib has been approved by the United States Food and Drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Napolitano, Maria, D’Amico, Ferdinando, Ragaini, Elisa, Peyrin-Biroulet, Laurent, Danese, Silvio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9211104/ https://www.ncbi.nlm.nih.gov/pubmed/35747444 http://dx.doi.org/10.2147/DDDT.S340459

Ejemplares similares

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
por: Solitano, Virginia, et al.
Publicado: (2020)

Early Intervention in Ulcerative Colitis: Ready for Prime Time?
por: Solitano, Virginia, et al.
Publicado: (2020)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience
por: D’Amico, Ferdinando, et al.
Publicado: (2019)

Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn’s and Colitis Organization
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Efficacy and Safety of S1P1 Receptor Modulator Drugs for Patients with Moderate-to-Severe Ulcerative Colitis
por: Bencardino, Sarah, et al.
Publicado: (2023)

Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

International Consensus on Definition of Mild-to-Moderate Ulcerative Colitis Disease Activity in Adult Patients
por: Caron, Bénédicte, et al.
Publicado: (2023)

Predictive value of Milan ultrasound criteria in ulcerative colitis: A prospective observational cohort study
por: Allocca, Mariangela, et al.
Publicado: (2022)

Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD)
por: Furfaro, Federica, et al.
Publicado: (2022)

SARS-CoV-2 vaccination in IBD: more pros than cons
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Diarrhea During COVID-19 Infection: Pathogenesis, Epidemiology, Prevention, and Management
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Ulcerative colitis: Impact of early disease clearance on long‐term outcomes ‐ A multicenter cohort study
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Which MRI Score and Technique Should Be Used for Assessing Crohn’s Disease Activity?
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge
por: Wils, Pauline, et al.
Publicado: (2022)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Risk-Benefit of IBD Drugs: A Physicians and Patients Survey
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey
por: D'Amico, Ferdinando, et al.
Publicado: (2020)

The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases
por: Solitano, Virginia, et al.
Publicado: (2021)

Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis
por: Ernest-Suarez, Kenneth, et al.
Publicado: (2023)

Upadacitinib Treatment Improves Symptoms of Bowel Urgency and Abdominal Pain, and Correlates With Quality of Life Improvements in Patients With Moderate to Severe Ulcerative Colitis
por: Ghosh, Subrata, et al.
Publicado: (2021)

Accuracy of Humanitas Ultrasound Criteria in Assessing Disease Activity and Severity in Ulcerative Colitis: A Prospective Study
por: Allocca, Mariangela, et al.
Publicado: (2018)

Real‐world use of endoscopic and histological indices in ulcerative colitis: Results of a global survey
por: Nardone, Olga Maria, et al.
Publicado: (2023)

Quality of Life and Work Productivity Improvements with Upadacitinib: Phase 2b Evidence from Patients with Moderate to Severe Crohn’s Disease
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2021)

Is Hartmann’s Pouch an Option in the Management of Acute Severe Ulcerative Colitis?
por: Renaud, Myriam, et al.
Publicado: (2022)

Effectiveness of budesonide MMX (Cortiment) for the treatment of mild-to-moderate active ulcerative colitis: study protocol for a prospective multicentre observational cohort study
por: Danese, Silvio, et al.
Publicado: (2016)

Milan ultrasound criteria are accurate in assessing disease activity in ulcerative colitis: external validation
por: Allocca, Mariangela, et al.
Publicado: (2021)

LIAISON(®) Calprotectin for the prediction of relapse in quiescent ulcerative colitis: The EuReCa study
por: Fiorino, Gionata, et al.
Publicado: (2022)

New Technologies in Digestive Endoscopy for Ulcerative Colitis Patients
por: Biamonte, Paolo, et al.
Publicado: (2023)

Setting up a Virtual Calprotectin Clinic in Inflammatory Bowel Diseases: Literature Review and Nancy Experience
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_94inh6n3tojkog5bnu2v8giafa